



Collaborative Approach to Life Science Financing

Statements in this presentation that are not strictly historical, and any statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our Annual Report on Form 10-K for the year ended December 31, 2018 and our Quarterly Reports on Form 10-Q for subsequent periods. The Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

Our specialty finance and asset management businesses are conducted through separate subsidiaries and the Company conducts its operations in a manner that is excluded from the definition of an investment company and exempt from registration and regulation under the Investment Company Act of 1940.

This presentation is neither an offer to sell nor a solicitation of any offer to buy any securities, investment product or investment advisory services, including such services offered by SWK Advisors LLC. This presentation does not contain all of the information necessary to make an investment decision, including, but not limited to, the risks, fees and investment strategies of investing in life science investments. Any offering is made only pursuant to the relevant information memorandum, a relevant subscription agreement or investment management agreement, and SWK Advisors LLC's Form ADV, all of which must be read in their entirety. All investors must be "accredited investors" and/or "qualified purchasers" as defined in the securities laws before they can invest with SWK Advisors LLC.

Life science securities may rely on milestone payments and/or a royalty stream from an underlying drug, device, or product which may or may not have received approval of the Food and Drug Administration ("FDA"). If the underlying drug, device, or product does not receive FDA approval, it could negatively impact the securities, including the payments of principal and/or interest. In addition, the introduction of new drugs, devices, or products onto the market could negatively impact the securities, since that may decrease sales and/or prices of the underlying drug, device, or product. Changes to Medicare reimbursement or third party payor pricing could negatively impact the securities, since they could negatively impact the prices and/or sales of the underlying drug, device, or product. There is also risk that the licensing agreement that governs the payment of royalties may terminate, which could negatively impact the securities. There is also the risk that litigation involving the underlying drug, device, or product could negatively impact the securities, including payments of principal and/or interest on any securities.



Custom financing solutions for commercial-stage healthcare companies and royalty owners

Underserved, High- Need Market	 SWK targets \$5mm to \$20mm financings, a market niche that is largely ignored by larger market participants and generates attractive full-cycle returns Business focus is secured financings and royalty monetizations, but will selectively consider equity-like opportunities and M&A
Demonstrated Success, Attractive Returns	 Targets unlevered, mid-teens return on capital with a portfolio effective yield of 13.8% for 3Q19 Financings with 23 parties as of November 13, 2019 17 exits from inception through November 13, 2019 generating a 19% IRR and 1.2x MOIC Completed financings encompass 36 different parties deploying \$528mm of capital Compounded book value per share at a 11% CAGR from 4Q12 to 3Q19's \$17.63
Targeting Multiple Growth Opportunities	 Recent Enteris BioPharma acquisition and NASDAQ uplist plan part of "transformational" growth strategy ✓ Increase book value per share at a 10%+ CAGR ✓ Be recognized as partner of choice for life science companies and inventors seeking \$20mm or less ✓ Generate current income to utilize SWK's substantial NOL asset, \$377mm at December 31, 2018 Experienced and aligned management and Board



Life Science Finance Opportunity

Achieve high current yield from investment in non-correlated assets

Access to capital is challenging for small/midsized life science cos - Few participants exist for sub-\$20mm life science financings

Life science products are highly portable


- Approved & marketed products and/or royalty streams are valuable collateral

Revenues are predictable and have low correlation to economic growth and macro factors

Mitigate FDA & clinical trial risk by focusing on commercial opportunities



Value Creation Strategy




SWK believes this strategy can continue to achieve a 10%+ book value per share CAGR





finance strategy

SWK HOLDINGS




* GAAP value at September 30, 2019; does not include capital advances made subsequent to quarter end


****** Finance Receivables plus Corporate Debt Securities


*** Private warrants carried at zero cost/not valued on balance sheet




Financial Snapshot










* Defined as finance receivables, corporate debt securities, and investment in unconsolidated entity less non-controlling interests

** During 2017 SWK incurred a \$15.7mm provision for income taxes to reduce the carrying value of the deferred tax asset to account for a reduction in the statutory tax rate

*** Eliminates provision for income taxes and non-cash mark-to-market changes on public equity & warrant assets and liability; see reconciliation on page 27; LTM period includes \$1.1mm of Enteris transaction expenses



SWK Targets Low-to-Mid Teens Effective Yields 3Q19 Effective Yield of 13.8%



^{*} Includes non-accruals, marketable investments, and corporate debt securities; excludes marketable securities and warrants

** Includes non-accruals; effective yield is the rate at which income is expected to be recognized pursuant to the Company's revenue recognition policies, if all payments are received pursuant to the terms of the finance receivable; excludes warrants



Current Structured Credit Portfolio





Current Royalty Portfolio

Beleodaq* (belinostat) for injection tr intervent infection	Besivance	Advanced Biomarker Technologies	CAMBIA	Forfivo XL bupropion HCL EXTENDED 4ELEASE TABLETS 450 MG	* NARCAN (relevane HO) NASAL SPRAY 4mg	TRT
Beleodaq (Onxeo) 06.06.18 \$7.5 million – Royalty Acquisition	Besivance 04.02.13 \$16 million – Royalty Acquisition	ABT 10.10.14 \$5.8 million – Structured Credit	Cambia 07.31.14 \$9.5 million – Royalty Acquisition	ForFivo (IntelGenx) 08.05.16 \$6 million – Royalty Acquisition	Narcan (Opiant) 11.07.16 \$17.5 million – Royalty Acquisition	Tissue Regeneration Therapeutics 06.12.13 \$3.3 million – Royalty Acquisition

Portfolio Realizations

- As of November 13, 2019 SWK has exited 17 financings for a total 1.2x CoC return and 19% weighted average IRR
 - 14 resulted in positive realizations with a cumulative 1.4x CoC and weighted average 31% IRR
 - SynCardia position was sold to distressed private equity firm with SWK recouping 58% of principal
 - Response Genetics exited via Chapter 11 and sold to a strategic buyer for cash and CGIX stock with SWK recouping 47% of principal
 - Hooper and Hooper II loans cumulatively resulted in an aggregate \$0.4mm loss/0.98x CoC return

Investments	Origination	Payoff	Cost*	P	roceeds	CoC	IRR	Notes
Nautilus	12/05/12	12/17/13	\$ 22,500	\$	28,269	1.3x	26%	Keyasset was Cambia
Parnell	01/23/14	06/27/14	25,000		27,110	1.1x	21%	
PDI	10/31/14	12/22/15	20,000		25,028	1.3x	23%	
Tribute	08/08/13	02/05/16	14,000		18,367	1.3x	16%	
Galil	10/31/14	06/15/16	12,500		16,601	1.3x	21%	
Nanosphere	05/14/15	06/30/16	10,000		14,362	1.4x	48%	
Syncardia First	12/13/13	06/24/16	12,688		8,524	0.7x	-30%	
Syncardia Second	12/13/13	06/24/16	5,850		3,255	0.6x	-39%	
Syncardia Preferred	09/15/14	06/24/16	1,500		-	0.0x	-100%	
Response Genetics	07/30/14	10/07/15	12,257		5,780	0.5x	-47%	
Holmdel	12/20/12	02/23/17	6,000		21,084	3.5x	63%	
Hooper	04/17/15	05/12/17	5,000		6,754	1.4x	20%	
Narcan	12/12/16	02/28/18	17,500		29,245	1.7x	70%	Continue to own 10% of the royalty
OraMetrix	12/15/16	05/01/18	8,500		10,603	1.2x	19%	
Parnell	11/22/16	07/30/18	13,500		19,327	1.4x	26%	
Hooper II	05/12/17	10/10/18	21,340		19,162	0.9x	-16%	
EyePoint	03/28/18	02/13/19	20,000		25,168	1.3x	34%	Continue to own warrants
Thermedx	05/05/16	05/22/19	3,500		5,303	1.5x	18%	Includes par value of \$343 retained sub note
Cheetah Medical	01/15/19	09/30/19	 10,000		12,434	1.2x	32%	Excludes \$211k of potential earnouts
Total Realized / Wtd.	Avg		\$ 241,634	\$	296,375	1.2 x	19%	-

*Cost measured as principal advanced at deal close and additional add-ons, including time-weighted restructuring fundings

Portfolio Realizations to Strategic Buyers

- Ten realizations to strategic buyers demonstrated a median 30% LTV of SWK's original loan value
- Seven of the ten businesses were not profitable at time of sale, validating SWK's revenue and IP-based underwriting methodology

\$ in mm

								Target Profitable	
		Closing	Transaction	SWK Loan	SWK Loan /	LTM	EV/LTM	at Time of	
Target	Buyer	Date	EV	at Cost*	Transaction	Sales	Sales	Sale?	Notes
Nautilus	Depomed	12/17/13	\$ 48.7	\$ 22.5	46%	\$ 15.4	3.2x	Ν	
Response Genetics	Cancer Genetics	10/07/15	5.8	12.3	213%	16.7	0.3x	Ν	Cash received at closing, AR proceeds, and realized value of CGIX equity
PDI	Publicis	12/22/15	33.0	20.0	61%	129.3	0.3x	Y	CSO Division Only; Transaction EV assumes 50% near-term earn-outs achieved
Tribute	Aralez	2/1/16	147.6	14.0	9%	26.5	5.6x	Ν	
Galil	BTG plc	5/16/16	84.4	12.5	15%	22.7	3.7x	Ν	Transaction EV excludes up to \$25.5mm of additional milestones
Nanosphere	Luminex	6/30/16	77.0	25.0	32%	23.1	3.3x	Ν	
InnoPran XL**	ANI Pharma	2/23/17	30.5	6.0	28%	11.1	2.7x	Y	
Orametrix	Dentsply Sirona	5/1/18	90.0	8.5	9%	20.0	4.5x	Y	Transaction EV excludes up to \$60mm in earn-outs
Hooper II	Quest	10/10/18	27.8	26.6	96%	61.3	0.5x	Ν	Loan value includes non-SWK revolver (\$7.6mm); Workout fees totaled \$4.4mm
Cheetah Medical	Baxter	10/24/19	190.0	20.0	11%	22.2	8.6x	Ν	Transaction EV excludes up to \$40mm in earn-outs (\$25 already 'earned')
Median					30%		3.3x		


*Cost measured as greatest of principal advanced at deal close and additional add-ons, including restructuring fundings

**InnoPran XL was the primary asset of Holmdel Pharmaceuticals, LP



Sourcing

- SWK has a well-developed and diversified sourcing network
 - SWK balances proprietary opportunities with deal flow from trusted, boutique investment banks and brokers
- SWK typically faces limited competition due to proprietary sourcing network and focus on sub-\$20mm financings
- The deals completed from 2016 through 2018 were sourced from a variety of relationships:





Financing Structures

Structured Debt Royalties Synthetic Royalty Hybrid Financing Product Acquisition

- Primarily first lien senior secured loans, though will selectively evaluate second lien opportunities
- Typically include covenants, prepayment penalties, origination and exit fees, and warrant coverage
- Provide working capital to support product commercialization and M&A
- Companies: fund pipeline development & leverage a lower cost of capital for higher ROI projects
- Institutions: capital planning for operating budgets, funding R&D initiatives, & financial asset diversification
- Inventors: financial asset diversification, fund start-up company
- Marketer creates a 'royalty' by selling an interest in a future revenue stream earned with a single product or basket of products in exchange for an upfront payment and potential future payments
- Ability to structure tiered revenues, reverse tiers, minimum payments, caps, step-downs and buy-out options, similar to a license agreement between innovator and marketer
- Combination of royalty and revenue-based financings
- Can take on many forms, including structured debt and equity investments
- Target legacy products with established revenue trends, minimal marketing and infrastructure requirements



Asset base and nimble structure position SWK to serve the sub-\$20mm financing market

- Smaller companies often don't have financial profile to qualify for traditional financing sources
- Companies in this niche often have few options outside of a dilutive equity raise
- The IPO market is largely closed to companies of this size requiring expensive and difficult private equity sourcing
- Many alternative financing sources have grown too large to care about smaller companies
- Some historical financing sources have been acquired by regulated financial institutions that due to regulatory constraints cannot lend to unprofitable companies and prohibit SWK-style transactions
- Venture lenders often require principal payback over a shorter period than SWK's structure

Structures financings to preserve liquidity and match a growing company's revenue profile

Provides its borrowers with access to its network of capital markets resources and operators

Through RIA arm and industry relationships, SWK can access additional capital to finance larger opportunities



Historical Financing: Narcan Royalty

Narcan is the only FDA approved, intranasal Naloxone product for the treatment of opioid overdose Narcan is appropriately priced with revenue growth from expanded distribution, not price hikes

OPPORTUNITY

- Opiant is a publicly traded drug development company that receives a royalty on Narcan for developing the drug's unique formulation
 - Novel formulation has a faster time to onset and more convenient and safer administration
- Opiant needed capital to pursue development programs
- At time of monetization, Opiant was a thinly traded OTC stock and management believed the share price did not reflect underlying asset value, thus a share offering was not an attractive option

SOLUTION

- SWK structured a capped royalty that was smaller than competing proposals, and allowed Opiant to retain tail economics
- In December 2016, SWK funded \$13.8mm in exchange for a royalty that was capped at a 1.5x CoC return
 - On August 8, 2017 upon achieving \$25mm in cumulative sales during two consecutive quarters, SWK funded additional \$3.8mm with a 1.5x CoC return cap
- Narcan sales exceeded forecasts; CoC return cap achieved in February 2018
- SWK retains a residual royalty ranging from 5% to 10% through expiry of Narcan IP



Historical Financing: Galil Medical

Galil is a privately-held medical device company that delivers innovative cryotherapy solutions for tumor ablation

OPPORTUNITY

- In 2014, Galil was on the cusp of accelerating revenue growth, but was not yet cash-flow positive and could not tap traditional financing channels
- Galil needed additional capital to run clinical trials and expand its sales force

SOLUTION

- In December 2014, SWK provided a \$12.5mm senior secured term loan structured to delay principal repayment until growth initiatives matured
- In late 2015, SWK committed to provide additional financing to support Galil's proposed acquisition of a competitor
 - The transaction was not consummated, but SWK's support permitted opportunistic bid
- By early 2016, the growth initiatives were bearing fruit, and in June 2016, Galil was acquired by BTG plc for \$84mm plus up to \$26mm in earn-outs
- The SWK facility gave Galil capital to grow the business and garner a higher acquisition price while allowing the equity owners to capture maximum upside
- SWK facility represented 15% LTV of the take-out price
- SWK generated a 1.3x cash-on-cash return and 20% IRR



Synergistic & Value Enhancing

Highly Favorable Deal Economics

"Game-Changing" Platform Technology

Strong Company; Positioned for Success

- Natural extension to SWK's existing royalty monetization business, which generates income via royalties on life science products in a mix of structures
- Enteris offers opportunity to create wholly-owned portfolio of milestones and royalties on IP-protected biotherapeutics with substantial upside optionality
- Attractive valuation with SWK buying undervalued portfolio of "call options" of current & future licenses, owned drug candidate assets, and manufacturing operations
- Risk-adjusted economics from existing/expected licenses anticipated to exceed purchase price
- SWK believes near to medium term licenses may exceed \$50.0mm of milestones and royalties
- Peptelligence[®] enables injectable-to-oral conversion of peptides and difficult to formulate small molecules
- Targets substantial market and serves as cornerstone for "asset-light" licensing revenue model
- Franchise-like model ("multiple shots on goal") leverages partners' significant R&D and marketing/commercialization spend
- Existing 505(b)(2) pharmaceutical development candidates plus ability to internally expand owned-product portfolio creates engine for additional future licenses
- Enteris possesses proven technology, clinical experience and in-house manufacturing which is unique compared with peers, some of which sport multi-hundred million dollar market values
- Potential to expand Peptelligence platform via acquisition of dosing technologies and CDMO assets



Proven Technology, Late-Stage Commercial Partnerships, and Internal Pipeline

Drug Delivery Technology

- Peptelligence technology allows for oral delivery of drugs that are typically injected, including peptides and BCS class II, III, and IV small molecules
- Extensive intellectual property estate with protection through 2036

Commercial Platform

- Generates revenue three ways:
 - Formulation and development work
 - Clinical trial tablet manufacturing
 - Technology licenses consisting of milestones and royalties
- Peptelligence licenses with Cara Therapeutics, Ferring Pharmaceuticals and R-Pharm, and development work with several large pharmaceutical partners

Internal 505(b)(2) Pipeline

- Ovarest[®] (oral leuprolide tablet)
 First indication: Endometriosis
- TobrateTM (oral tobramycin tablet)
 - First indication: Uncomplicated Urinary Tract Infection
- Oral Octreotide Tablet
 - First indication: Neuroendocrine tumors

Company Highlights

- Privately held company based in Boonton, New Jersey
- To operate as a wholly-owned subsidiary, run by current experienced team
- Expected to be profitable including anticipated license-related revenue
- Over time SWK anticipates Enteris will develop multiple "shots on goal" value proposition



Transaction Overview

- \$21.5mm paid upfront to acquire 100% of Enteris' capital stock
- Proceeds from Cara Therapeutics licensing agreement, which includes milestone payments and low-single digit royalties on sales of Oral KorsuvaTM:
 - Seller will receive 100% of \$8.0mm upfront payment
 - SWK will receive 60% of the first milestone payment
 - SWK will receive 25% of all other milestone payments until seller receives \$32.75mm in aggregate consideration
 - License revenue split 50%/50% thereafter
 - SWK portion of this license's economics are expected to be greater than the purchase price
- If out-licensed, proceeds for Enteris' 505(b)(2) drug candidates Ovarest and Tobrate
 - SWK to receive 40% until seller receives \$3.0mm on each asset
 - SWK to receive 70% of milestone and royalty proceeds thereafter
- If out-licensed, SWK will receive 90% of Enteris' 505(b)(2) octreotide oral drug candidate proceeds
- Enteris to operate as a stand-alone business unit with the existing management team reporting directly to SWK CEO Winston Black



Leadership Team



Winston Black Chief Executive Officer

- Appointed CEO in 2016
- Co-founded PBS Capital Management
- Prior leadership positions at Highland Capital Management, Mallette Capital Management and ATX Communications



Charles Jacobsen Chief Financial Officer

- Appointed CFO in 2012
- Currently serves as Partner of Strategic Growth for CFGI
- Has served in CEO and CFO roles at multiple financing and investment firms



Jody Staggs Vice President

- Joined in 2015
- Previously VP of Investments at Annandale Capital
- Co-founded PBS Capital Management
- Prior to PBS, served as Senior Portfolio Analyst at Highland Capital



Yvette Heinrichson Controller

- Joined in 2016
- Proficient in technical GAAP accounting, SEC financial reporting, SOX implementation
- Served as financial statement auditor and tax professional with Deloitte for multiple years



SWK – Rapidly-Growing Life Science Focused Specialty Finance Company

Custom financing solutions for commercial-stage healthcare companies and royalty owners

Targeting \$5mm to \$20mm financings, a niche that is largely ignored by larger market participants


Focus is secured financings and royalty monetizations, but will selectively consider equity-like opportunities and M&A (Enteris BioPharma)

Since 2012, SWK has completed financings with 36 different parties deploying \$528mm of capital, including partner co-investments



Balance Sheet

\$ in 000s		Sep-19		Dec-18		Dec-17		Dec-16		Dec-15
ASSETS										
Cash and cash equivalents	\$	4,486	\$	20,227	\$	30,557	\$	32,182	\$	47,287
Accounts receivable		2,452		2,195		1,637		1,054		1,127
Finance receivables		175,048		166,610		151,995		126,366		99,346
Marketable investments		1,946		-		1,856		2,621		5,286
Corporate Debt Security		483		532		-		-		-
Investment in unconsolidated entities		-		-		-		6,985		7,988
Deferred tax asset		20,098		22,684		22,725		38,471		16,833
Warrant assets		2,940		2,777		987		1,013		1,900
Intangible assets, net		32,703		-		-		-		-
Goodwill		4,602		-		-		-		-
Fixed assets, net		1,259		25		-		-		-
Other assets		1,518		612		126		240		720
Total assets	\$	247,535	\$	215,662	\$	209,883	\$	208,932	\$	180,487
LIABILITIES AND STOCKHOLDERS' EQUITY										
Accounts payable and accrued liabilities	\$	3,506	\$	2,592	ć	1,840	ć	682	ć	788
Revolving Credit Facility	Ļ	5,500	Ļ	2,352	Ļ	1,040	Ļ		Ļ	/00
Contingent consideration payable		16,274		_		_		_		
Warrant liability		10,274		13		91		189		259
Total liabilities		19,907		2,605		1,931		871		1,047
Stockholders' equity:		15,507		2,005		1,551		071		1,047
Preferred stock		_		-		-		_		_
Common stock		13		13		13		13		13
Additional paid-in-capital		4,432,027		4,432,499		4,433,589		4,433,289		4,432,926
Accumulated deficit		4,204,412)		(4,219,455)		(4,225,863)		(4,228,910)		(4,257,798)
Accumulated other comprehensive income	,					213	`	(87)		-
Totak SWK Holdings Corp stockholders' equity		227,628		213,057		207,952		204,305		175,141
Non-controlling interests in consolidated entities								3,756		4,299
Total stockholders' equity		227,628		213,057		207,952		208,061		179,440
Total liabilities and stockholders' equity	\$		\$		\$		\$	208,932	\$	
Stockholders' Equity Excluding DTA		207,530		190,373		185,227		165,834		158,308





Income Statement

\$ in 000s	LTM	Dec-18	Dec-17	Dec-16	Dec-15
Revenues					
Finance receivable interest income, including fees	\$ 27,758	\$ 25 <i>,</i> 978	\$ 26,877	\$ 15,747	\$ 17,265
Pharmaceutical development services	149	-	-	-	-
Marketable investments interest income	-	-	-	92	266
Income related to investments in unconsolidated entities	-	-	10,530	6,219	5,884
Other	6	12	79	322	45
Total Revenues	27,913	25,990	37,486	22,380	23,460
Costs and expenses:					
Provision for credit losses	609	6,179	-	1,659	10,848
Impairment expense	76	7,875	8,509	8,077	6,638
Interest expense	339	160	-	-	381
Pharmaceutical manufacturing, research and development	286	-	-	-	-
Depreciation and amortization	356	-	-	-	-
General and administrative	6,547	4,883	4,101	2,829	3,378
Total costs and expenses	8,213	19,097	12,610	12,565	21,245
Other income (expense), net					
Unrealized net (loss) gain on warrants	(543)	484	(1,115)	588	(3 <i>,</i> 305)
Unrealized net (loss) gain on equity securities	2,352	-	-	-	-
Unrealized net (loss) gain on investments	-	-	-	-	-
Loss on write off of investments	87	-	-	-	-
Equity investment losses	(1,035)	(1,035)	-	-	-
Gain/(loss) on sale/(write off) of investments	(105)	(105)	243	-	-
Income (loss) before income taxes	20,456	6,237	24,004	10,403	(1,090)
Income tax (benefit) expense	814	42	15,753	(21,638)	3,273
Consolidated net income (loss)	19,642	6,195	8,251	32,041	(4,363)
Net income attributable to non-controlling interests	-	-	5,204	3,153	3,007
Net income (loss) attributable to SWK Holdings Corp Stockholders	\$ 19,642	\$ 6,195	\$ 3,047	\$ 28,888	\$ (7,370)

Net income (loss) per share attributable to SWK Holdings Corp Stockholders

	5 1					
Basic		\$ 1.52	\$ 0.47	\$ 0.23	\$ 2.22	\$ (0.57)
Diluted		\$ 1.52	\$ 0.47	\$ 0.23	\$ 2.22	\$ (0.57)
Weighted Average Shares						
Basic		 12,911	13,051	13,036	13,015	12,986
Diluted	25	12,913	13,054	13,040	13,018	12,986



Cash Flow Statement

\$ in 000s,*	LTM	Dec-18	Dec-17	Dec-16	Dec-15
Cash flows from operating activities:					
Consolidated net income	\$19,642	\$6,195	\$8,251	\$32,041	(\$4,363)
Adjustments to reconcile net income to net cash provided by operating activities:					,
Income from investments in unconsolidated entity	-	-	(10,530)	(6,219)	(5,884)
Provision for loan credit losses	609	6,179	-	1,659	10,848
Impairment expense	76	7,875	8,509	8,077	6,638
Amortization of debt issuance costs	140	-		-,	-
Change in fair value of warrants	543	(484)	1,115	(588)	3,305
Change in fair value of equity securities	(2,352)	()	_,	()	-)
Gain on sale of marketable securities	18	105	(243)	-	-
Deferred income tax	803	31	15,745	(21,638)	3,273
Loan discount amortization and fee accretion	627	487	(1,926)	(3,109)	(1,778)
Interest income in excess of cash collected	(145)	(249)	(534)	(0)200)	(1,063)
Interest paid-in-kind	(922)	(191)	(1,779)	(398)	(1,005)
Stock-based compensation	408	267	300	363	640
Equity Investment Losses	1,035	1,035	- 500	505	
Gain (loss) on sale (write off) of investments	1,035	1,035	_		
Depreciation and Amortization Expense	356	_	-	_	-
Other	28	- 28	- 17	- 16	- 391
Changes in operating assets and liabilities:	20	20	17	10	391
Accounts receivable	(443)	(558)	(583)	(59)	(74)
Other assets		202	(383)	(396)	(74) (648)
	(65) (2,304)	(1,296)	(42)	(106)	, ,
Accounts payable and other liabilities		\$ 19,626		1 /	(76) \$ 11,209
Net cash provided by operating activities	\$ 18,054	\$ 19,020	\$ 19,458	\$ 9,643	\$ 11,209
Cash flows from investing activities:					
Acquisition of business, net of cash acquired	(19,707)	-	-	-	-
Investment in equity securities	(159)	-	-	-	-
Cash distributions from investments in unconsolidated entity	-	-	17,515	7,222	6,940
Cash received for settlement of warrants	-	-	-	1,405	-
Proceeds from sale of available-for-sale marketable securities	221	221	345	-	-
Investment in finance receviables	27,351	-	-	-	-
Repayment of finance receivables	(9,912)	-	-	-	-
Net (increase) decrease in finance receivables	(28,404)	(28,404)	(30,064)	(29,717)	(25,849)
Investment in marketable investments	-	-	-	-	-
Corporate debt security principal payment	63	69	93	41	80
Other	(108)	(16)	(12)	(3)	(50)
Net cash provided by investing activities	\$ (30,655)	\$ (28,130)	\$ (12,123)	\$ (21,052)	\$ (18,879)
Cash flows from financing activities:					
Distribution to non-controlling interests	-	-	(8,960)	(3,696)	(3,575)
Repurchases of common stock, including fees & expenses	(2,166)	(1,357)	-	-	-
Debt Issuance Costs	39	(469)	-	-	-
Net cash used in financing activities	\$ (2,127)	\$ (1,826)	\$ (8,960)	\$ (3,696)	\$ (3,771)
Net increase in cash and cash equivalents	(14,728)	(10,330)	(1,625)	(15,105)	(11,441)
Cash and cash equivalents at beginning of period	19,214	30,557	32,182	47,287	58,728
Cash and cash equivalents at end of period		\$ 20,227	,	\$ 32,182	\$ 47,287



Reconciliation of Non-GAAP Adjusted Net Income

The table below eliminates provisions for income taxes, non-cash mark-to-market changes on warrant assets and SWK's warrant liability, as well as, warrant-related debt issuance costs and stock compensation expense related to SWK's equity raise. The following tables provide a reconciliation of SWK's reported (GAAP) income before provision for income tax to SWK's adjusted net income attributable (Non-GAAP) for the periods denoted in the table:

\$ in 000s	LTM	Dec-18	Dec-17	Dec-16	Dec-15
Consolidated net income (loss)	\$ 19,643	\$ 6,195	\$ 8,251	\$ 32,041	\$ (4,363)
Plus: income tax expense (benefit)	814	42	15,753	(21,638)	3,273
Plus: loss (gain) on fair market value of warrants	1,578	551	1,115	(588)	3,305
Plus: loss (gain) on Fair Market Value of Equity Securities	(565)	-	-	-	-
Plus: loss related to Response Genetics warrants	-	-	-	-	(802)
Plus: warrant-related debt issuance costs	-	-	-	-	155
Plus: depreciation and amortization	373	17			
Adjusted income before provision for income tax	\$ 21,843	\$ 6,805	\$ 25,119	\$ 9,815	\$ 1,568
Plus: Adjusted provision for income tax	-	-	-	-	-
Non-GAAP consolidated net income	\$ 21,843	\$ 6,805	\$ 25,119	\$ 9,815	\$ 1,568
Less: Non-GAAP adjusted net income attributable to non-controlling interest	-	-	(5,204)	(3,153)	(3,007)
Non-GAAP adjusted net income (loss) attributable to SWK Holdings Corporation Stockholders	\$ 21,843	\$ 6,805	\$ 19,915	\$ 6,662	\$ (1,439)



- Winston Black:
 - Phone: 972.687.7251
 - Email: wblack@swkhold.com
- Jody Staggs:
 - Phone: 972.687.7252
 - Email: jstaggs@swkhold.com
- Office address:
 - 14755 Preston Road, Ste 105
 - Dallas, TX 75254
- Website: www.swkhold.com







Collaborative Approach to Life Science Financing